GMAB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.03B

+14.81%

0.434

-48.04%

961.58M

+35.06%

0.000

-100%

1.07B

+15.01%

0.000

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Genmab A/S (GMAB) for FY2025, with the revenue forecasts being adjusted by 2.23% over the past three months. During the same period, the stock price has changed by 7.70%.

Revenue Estimates for FY2025

Revise Upward

+2.23%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.58%

In Past 3 Month

Stock Price

Go Up

+7.70%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 41.00 USD with a low forecast of 32.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

32.00

Averages

41.00

High

48.00

Current: 0.000

Low

32.00

Averages

41.00

High

48.00

Deutsche Bank

Buy

maintain

2026-01-08

New

Reason

Deutsche Bank

Price Target

2026-01-08

New

maintain

Buy

Reason

Deutsche Bank raised the firm's price target on Genmab to DKK 2,400 from DKK 2,000 and keeps a Buy rating on the shares.

Barclays

NULL -> Overweight

maintain

2026-01-06

New

Reason

Barclays

Price Target

2026-01-06

New

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Genmab to DKK 2,500 from DKK 2,000 and keeps an Overweight rating on the shares.

Deutsche Bank

Buy

maintain

2026-01-06

New

Reason

Deutsche Bank

Price Target

2026-01-06

New

maintain

Buy

Reason

Deutsche Bank raised the firm's price target on Genmab to DKK 2,400 from DKK 2,000 and keeps a Buy rating on the shares.

Guggenheim

Buy

maintain

$45

2025-12-30

Reason

Guggenheim

Price Target

$45

2025-12-30

maintain

Buy

Reason

After Genmab announced it will discontinue further clinical development of acasunlimab, Guggenheim calls this "a good decision by management" given that the firm had no value reflected in its model and estimates for acasunlimab based on low conviction in the probability of success of this candidate. This news has no impact on the firm's positive investment thesis for Genmab, adds the analyst, who keeps a Buy rating and $45 price target on the shares.

H.C. Wainwright

Buy

maintain

$40 -> $41

2025-11-10

Reason

H.C. Wainwright

Price Target

$40 -> $41

2025-11-10

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Genmab to $41 from $40 and keeps a Buy rating on the shares following the Q3 report. Darzalex Faspro is now FDA approved in high-risk smoldering multiple myeloma, the analyst tells investors in a research note.

Citi

Buy -> Neutral

downgrade

$101 -> $97

2025-09-29

Reason

Citi

Price Target

$101 -> $97

2025-09-29

downgrade

Buy -> Neutral

Reason

Citi downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, down from $101, after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97.00 per share in an all-cash transaction, representing a transaction value of $8.0B. The firm views the possibility of a competing bid as very low.

Valuation Metrics

The current forward P/E ratio for Genmab A/S (GMAB.O) is 17.91, compared to its 5-year average forward P/E of 38.27. For a more detailed relative valuation and DCF analysis to assess Genmab A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

38.27

Current PE

17.91

Overvalued PE

65.33

Undervalued PE

11.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

27.68

Current EV/EBITDA

8.18

Overvalued EV/EBITDA

54.04

Undervalued EV/EBITDA

1.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.96

Current PS

4.63

Overvalued PS

15.51

Undervalued PS

4.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GMAB News & Events

Events Timeline

No data

News

7.5

01-07Benzinga

Genmab Partners with Anthropic to Enhance Data Processing Efficiency

3.5

01-07Newsfilter

Genmab Partners with Anthropic to Enhance R&D Efficiency

9.0

01-05Benzinga

Incyte's Tafasitamab Trial Achieves Key Milestones for DLBCL Treatment

People Also Watch

Frequently Asked Questions

What is Genmab A/S (GMAB) stock price today?

The current price of GMAB is 34.26 USD — it has increased 1.87 % in the last trading day.

What is Genmab A/S (GMAB)'s business?

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

What is the price predicton of GMAB Stock?

What is Genmab A/S (GMAB)'s revenue for the last quarter?

Genmab A/S revenue for the last quarter amounts to 1.02B USD, increased 25.25 % YoY.

What is Genmab A/S (GMAB)'s earnings per share (EPS) for the last quarter?

Genmab A/S. EPS for the last quarter amounts to 6.46 USD, increased 121.23 % YoY.

What changes have occurred in the market's expectations for Genmab A/S (GMAB)'s fundamentals?

How many employees does Genmab A/S (GMAB). have?

Genmab A/S (GMAB) has 2682 emplpoyees as of January 10 2026.

What is Genmab A/S (GMAB) market cap?

Today GMAB has the market capitalization of 21.10B USD.